Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 23, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Interferon gamma-1b

ACTIMMUNE/Interferon gamma-1b is a single-chain polypeptide containing 140 amino acids that is produced by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the recombinant protein. Interferon gamma-1b is part of a drug regimen used to treat Chronic Granulomatous Disease, or CGD. CGD is a genetic disorder, usually diagnosed in childhood, that affects some cells of the immune system and the body's ability to fight infections effectively.

BIOLOGICAL

Donor Leukocyte Infusion (DLI)

Donor lymphocyte infusion is a procedure that transfers healthy white blood cells (lymphocytes) from a bone marrow or stem cell donor to a recipient's blood. An infusion of healthy lymphocytes helps the recipient's immune system get rid of remaining cancer cells if they have a relapse after a bone marrow or stem cell transplant for blood cancer.

Trial Locations (3)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

63110

RECRUITING

Washington University, St Louis

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Evans MDS Discovery Research Grant

UNKNOWN

collaborator

Amgen

INDUSTRY

collaborator

FDA Office of Orphan Products Development

FED

lead

Sawa Ito, MD

OTHER

NCT06529731 - Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter